Tag Archives: Resverlogix

CETP Inhibitors: Blockbusters that Never Ran?

The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
Posted in Biotech, leadership, R&D, Technology | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta